Do you want to read an article? Please log in or register.
Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Lancet Respir Med.
Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group
doi: 10.1016/S2213-
RECOMMENDED
Pulmonary Fibrosis
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
Cheney J, Vidmar S, Gailer N, Wainwright C, Douglas TA, Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group.
doi: 10.1016/j.jcf.2020.02.022.
CoughPulmonary Fibrosis
The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial
Ronchetti K, Tame JD, Paisey C, Thia LP, Doull I, Howe R, Mahenthiralingam E, Forton JT
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis
Thorax.
Harun SN, Holford NHG, Grimwood K, Wainwright CE, Hennig S, Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group.
doi: 10.1136/
RECOMMENDED
Pulmonary Fibrosis
Lung Clearance Index to Track Acute Respiratory Events in School-age Children with Cystic Fibrosis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Perrem L, Stanojevic S, Shaw M, Jensen R, McDonald N, Isaac SM, Davis M, Clem C, Guido J, Jara S, France L, Solomon M, Grasemann H, Waters V, Sweezey N, Sanders DB, Davis SD, Ratjen F
doi: 10.1164/rccm.202006-2433OC.Visit the original publication at ncbi.nlm.nih.gov
Pulmonary FibrosisBronchi
Quantitative assessment of airway dimensions in young children with cystic fibrosis lung disease using chest computed tomography
Pediatr Pulmonol.
Kuo W, Soffers T, Andrinopoulou ER, Rosenow T, Ranganathan S, Turkovic L, Stick SM, Tiddens HAWM; AREST CF
doi: 10.1002/ppul.23787.
RECOMMENDED
CoughPulmonary Fibrosis
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA
doi: 10.1016/S2213-2600(21)00069-2
RECOMMENDED
Pulmonary Fibrosis
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
J Cyst Fibros.
Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G, VX15-661-113 Investigator Group.
doi: 10.1016/j.jcf.2019.06.009.